Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | MPO | P05164 | 2/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | MGMT | P16455 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4014567 | 0.83 | MPO (0.48) | MAOBIDO1MPOMGMTMAOA | |
| SCHEMBL4012289 | 0.82 | MPO (0.53) | MAOBIDO1AGXTMPONR4A2 | |
| SCHEMBL4011220 | 0.82 | MAOB (0.57) | MAOBIDO1MPONR4A2L3MBTL1 | |
| SCHEMBL3938044 | 0.79 | CYP4F2 (0.47) | MAOBMPOMAOA | |
| SCHEMBL3947954 | 0.74 | TAAR1 (0.51) | IDO1AGXTMPOL3MBTL1 | |
| SCHEMBL24968841 | 0.73 | MAOB (0.54) | MAOBIDO1AGXTMPOPARP10 | |
| SCHEMBL4012905 | 0.73 | MAOB (0.51) | MAOBIDO1MPO | |
| SCHEMBL4010774 | 0.73 | AGXT (0.60) | AGXT | |
| SCHEMBL1336494 | 0.71 | MAOB (0.58) | MAOBPARP10NR4A2MAOA | |
| SCHEMBL1379497 | 0.70 | MAOB (1.00) | MAOBIDO1AGXTPARP10NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009056886-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF FGFR ACTIVITY | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | WO | disclosed |
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009019518-A1 | PYRIMIDINE COMPOUNDS HAVING A FGFR INHIBITORY EFFECT | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | MAOB 695/4885IDO1 4109/4885AGXT 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.